Study of AZD3632 Monotherapy or in Combination with Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression

Trial Identifier: D8620C00001
Sponsor: AstraZeneca
Start Date: January 2026
Primary Completion Date: February 2029
Study Completion Date: February 2029
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Fitzroy, AU, 3065
AU Perth, AU, WA 6000
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
DE Dresden, DE, 01307
DE Frankfurt A. Main, DE, 60590
DE Halle (Saale), DE, 06097
DE Heidelberg, DE, 69120
DE München, DE, 81377
DE Ulm, DE, 89081
DK Copenhagen, DK, 2100
GB Edinburgh, GB, EH4 2XU
GB London, GB, EC1A 7BE
GB London, GB, SE5 9RS
GB Manchester, GB, M20 4BX
GB Newcastle, GB, NE7 7DN
IT Bologna, IT, 40138
IT Ravenna, IT, 48121
JP Bunkyo-ku, JP, 113-8677
JP Kashiwa, JP, 277-8577
JP Okayama, JP, 700-8558
KR seoul, KR, 06351
KR Seoul, KR, 110-744
KR Seoul, KR, 06591
US, IL Decatur, IL, US, 62526
US, NC Durham, NC, US, 27705
US, NY New York, NY, US, 10065
US, OR Portland, OR, US, 97239
US, Texas Houston, Texas, US, 77030